Literature DB >> 15006380

HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.

Gabriela Iurcu Mustata1, Alessandro Brigo, James M Briggs.   

Abstract

A three-dimensional pharmacophore model has been generated for HIV-1 integrase (HIV-1 IN) from known inhibitors. A dataset consisting of 26 inhibitors was selected on the basis of the information content of the structures and activity data as required by the catalyst/HypoGen program. Our model was able to predict the activity of other known HIV-1 IN inhibitors not included in the model generation, and can be further used to identify structurally diverse compounds with desired biological activity by virtual screening.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006380     DOI: 10.1016/j.bmcl.2004.01.027

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited.

Authors:  Jing Tang; Kasthuraiah Maddali; Yves Pommier; Yuk Y Sham; Zhengqiang Wang
Journal:  Bioorg Med Chem Lett       Date:  2010-04-21       Impact factor: 2.823

2.  Scaffold hopping for identification of novel D(2) antagonist based on 3D pharmacophore modelling of illoperidone analogs.

Authors:  Radha Charan Dash; Sharad H Bhosale; Suhas M Shelke; Mugdha R Suryawanshi; Ashish M Kanhed; Kakasaheb R Mahadik
Journal:  Mol Divers       Date:  2011-12-08       Impact factor: 2.943

3.  Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.

Authors:  Prashant Revan Murumkar; Vishal Prakash Zambre; Mange Ram Yadav
Journal:  J Comput Aided Mol Des       Date:  2010-02-24       Impact factor: 3.686

Review 4.  Computer tools in the discovery of HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

5.  3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.

Authors:  Jing Tang; Kasthuraiah Maddali; Mathieu Metifiot; Yuk Y Sham; Robert Vince; Yves Pommier; Zhengqiang Wang
Journal:  J Med Chem       Date:  2011-03-07       Impact factor: 7.446

6.  6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase.

Authors:  Jing Tang; Kasthuraiah Maddali; Christine D Dreis; Yuk Y Sham; Robert Vince; Yves Pommier; Zhengqiang Wang
Journal:  Bioorg Med Chem Lett       Date:  2011-02-18       Impact factor: 2.823

7.  Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).

Authors:  Devendra K Dhaked; Jitender Verma; Anil Saran; Evans C Coutinho
Journal:  J Mol Model       Date:  2008-12-02       Impact factor: 1.810

8.  Hybrid quantum mechanical/molecular mechanical molecular dynamics simulations of HIV-1 integrase/inhibitor complexes.

Authors:  Nadtanet Nunthaboot; Somsak Pianwanit; Vudhichai Parasuk; Jerry O Ebalunode; James M Briggs; Sirirat Kokpol
Journal:  Biophys J       Date:  2007-08-10       Impact factor: 4.033

9.  3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.

Authors:  Bulan Wu; Jing Tang; Daniel J Wilson; Andrew D Huber; Mary C Casey; Juan Ji; Jayakanth Kankanala; Jiashu Xie; Stefan G Sarafianos; Zhengqiang Wang
Journal:  J Med Chem       Date:  2016-06-17       Impact factor: 7.446

10.  Generation of predictive pharmacophore model for SARS-coronavirus main proteinase.

Authors:  Xue Wu Zhang; Yee Leng Yap; Ralf M Altmeyer
Journal:  Eur J Med Chem       Date:  2005-01       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.